Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Total Liabilities (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Total Liabilities for 14 consecutive years, with $401.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 14.53% year-over-year to $401.3 million, compared with a TTM value of $401.3 million through Dec 2025, up 14.53%, and an annual FY2025 reading of $401.3 million, up 14.53% over the prior year.
  • Total Liabilities was $401.3 million for Q4 2025 at Karyopharm Therapeutics, up from $365.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $401.3 million in Q4 2025 and bottomed at $314.5 million in Q1 2021.
  • Average Total Liabilities over 5 years is $364.8 million, with a median of $370.7 million recorded in 2023.
  • The sharpest move saw Total Liabilities skyrocketed 49.74% in 2021, then dropped 10.66% in 2025.
  • Year by year, Total Liabilities stood at $385.0 million in 2021, then decreased by 2.64% to $374.8 million in 2022, then increased by 0.48% to $376.6 million in 2023, then dropped by 6.96% to $350.4 million in 2024, then grew by 14.53% to $401.3 million in 2025.
  • Business Quant data shows Total Liabilities for KPTI at $401.3 million in Q4 2025, $365.5 million in Q3 2025, and $343.8 million in Q2 2025.